USP and Compendial Standards
Compendial standards are legally recognised pharmacopoeial monographs that fix a substance's identity, assay and impurity limits together with the analytical methods used to demonstrate them.
A compendial standard is a published monograph that fixes what a named substance must be: identity tests, an assay with acceptance limits, specified impurity limits, and the analytical method by which each is demonstrated. The United States Pharmacopeia and National Formulary, the European Pharmacopoeia and the Japanese Pharmacopoeia are the principal compendia, and general chapters supply the shared methods that individual monographs then reference rather than restate.
Monographs exist for peptides that have been in regulated use long enough to warrant the effort, oxytocin, glucagon, leuprolide acetate and octreotide acetate among them. A great many compounds sold into research channels have no monograph in any pharmacopoeia. Their status is non-compendial, meaning there is no published specification, no agreed method, and no threshold against which a batch could be judged to pass or fail.
That is the practical value of a monograph: it makes a quality claim falsifiable by someone other than the seller. With one in place, an independent laboratory can run the stated method and compare the result against a stated limit. Without one, the phrase meets specification refers to a specification the seller wrote, which may be silent on the impurities that matter most and is not comparable between suppliers.
The label that misleads most is pharmacopoeial grade attached to a compound that has no monograph. There is nothing for it to be graded against, so the phrase is decoration. A monograph for a bulk drug substance also does not make a finished preparation compliant, since the finished product carries its own requirements for sterility, endotoxin, container closure and stability that a raw-material monograph never addresses.